tiprankstipranks
Advertisement
Advertisement

NGEN Stock Latest News

NervGen Pharma initiated with a Buy at TD Cowen
The FlyNervGen Pharma initiated with a Buy at TD Cowen
5d ago
NGEN
NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program
PremiumCompany Announcements
NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program
14d ago
6K
NGEN
Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors
PremiumCompany Announcements
Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors
17d ago
NGEN
NervGen Reports Objective Neural Recovery Signal for NVG-291 in Chronic SCI Ahead of Phase 3
PremiumCompany Announcements
NervGen Reports Objective Neural Recovery Signal for NVG-291 in Chronic SCI Ahead of Phase 3
20d ago
6K
NGEN
NervGen Pharma files $250M mixed securities shelf
PremiumThe Fly
NervGen Pharma files $250M mixed securities shelf
20d ago
NGEN
NervGen Pharma announces biomechanical gait analyses on recovery with NVG-291
PremiumThe FlyNervGen Pharma announces biomechanical gait analyses on recovery with NVG-291
20d ago
NGEN
NervGen Pharma Launches Underwritten Public Offering to Fund NVG-291 Development
Premium
Company Announcements
NervGen Pharma Launches Underwritten Public Offering to Fund NVG-291 Development
24d ago
6K
NGEN
NervGen Pharma 24M share Spot Secondary priced at $2.50
Premium
The Fly
NervGen Pharma 24M share Spot Secondary priced at $2.50
24d ago
NGEN
NervGen Pharma secondary being re-offered at $2.50 per share
PremiumThe Fly
NervGen Pharma secondary being re-offered at $2.50 per share
25d ago
NGEN
NervGen Pharma announces common share offering, no amount given
PremiumThe Fly
NervGen Pharma announces common share offering, no amount given
25d ago
NGEN
NervGen Pharma Advances NVG-291 Toward Registrational Trial as Q1 2026 Loss Narrows
PremiumCompany Announcements
NervGen Pharma Advances NVG-291 Toward Registrational Trial as Q1 2026 Loss Narrows
28d ago
6K
NGEN
NervGen Pharma reports Q1 EPS (2c), consensus (7c)
PremiumThe Fly
NervGen Pharma reports Q1 EPS (2c), consensus (7c)
28d ago
NGEN
NervGen Pharma Narrows Quarterly Loss but Cash Reserves Decline in Q1 2026 Filing
PremiumCompany AnnouncementsNervGen Pharma Narrows Quarterly Loss but Cash Reserves Decline in Q1 2026 Filing
1M ago
6K
NGEN
NervGen Pharma Names New CFO and Wins Shareholder Backing for 2026 Equity Plan
Premium
Company Announcements
NervGen Pharma Names New CFO and Wins Shareholder Backing for 2026 Equity Plan
2M ago
6K
NGEN
NervGen Pharma appoints Keith Vendola as CFO
Premium
The Fly
NervGen Pharma appoints Keith Vendola as CFO
2M ago
NGEN
NervGen Pharma initiated with a Buy at H.C. Wainwright
PremiumThe Fly
NervGen Pharma initiated with a Buy at H.C. Wainwright
2M ago
NGEN
NervGen Pharma initiated with a Buy at Lucid Capital
PremiumThe Fly
NervGen Pharma initiated with a Buy at Lucid Capital
2M ago
NGEN
NervGen Pharma price target raised to $12 from $10 at Maxim
PremiumThe Fly
NervGen Pharma price target raised to $12 from $10 at Maxim
2M ago
NGEN
NervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia
PremiumCompany Announcements
NervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia
2M ago
NGEN
NervGen Pharma aligns with FDA on RESTORE study following End-of-Phase 2 meeting
PremiumThe FlyNervGen Pharma aligns with FDA on RESTORE study following End-of-Phase 2 meeting
2M ago
NGEN
NervGen Pharma price target lowered to $5.50 from $6.75 at Stifel
Premium
The Fly
NervGen Pharma price target lowered to $5.50 from $6.75 at Stifel
2M ago
NGEN
NervGen Pharma: Buy Rating on De‑Risked Path to Pivotal NVG-291 Trials and Compelling Risk‑Reward in Chronic Spinal Cord Injury
Premium
Ratings
NervGen Pharma: Buy Rating on De‑Risked Path to Pivotal NVG-291 Trials and Compelling Risk‑Reward in Chronic Spinal Cord Injury
3M ago
NGEN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >